story of the week
DLBCL and Indolent B-Cell Malignancies Can Be Effectively Treated With Anti-CD19 CAR T Cells
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
J. Clin. Oncol 2014 Aug 25;[EPub Ahead of Print], JN Kochenderfer, ME Dudley, SH Kassim, RPT Somerville, RO Carpenter, M Stetler-Stevenson, JC Yang, GQ Phan, MS Hughes, RM Sherry, M Raffeld, S Feldman, L Lu, YF Li, LT Ngo, A Goy, T Feldman, DE Spaner, ML Wang, CC Chen, S M Kranick, A Nath, DN Nathan, KE Morton, MA Toomey, SA RosenbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.